CAR-T Funding is Reaching Staggering New Heights
A survey reveals nearly US$100 market capitalisation
23 February 2021
A survey conducted by Washington DC based BioInformant assesses the growth of the CAR-T arm of immunotherapy research and development. The summary is posted below.
At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, and […]